IBRX Q3 2024 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+7346.3% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$80M-1314.3% margin

Net Income

-$86M-1404.0% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+483.2%

Cash Flow

Operating Cash Flow

-$99M

Free Cash Flow

-$102M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$365M

Total Liabilities

$1.1B

Stockholders' Equity

-$745M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$82,000	+7346.3%
Gross Profit	$6M	$82,000	+7346.3%
Operating Income	-$80M	-$80M	-0.1%
Net Income	-$86M	-$96M	+10.3%

Revenue Segments

Product

$6M98%

Product and Service, Other

$152,0002%